Ignite Creation Date:
2024-05-06 @ 8:27 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06383247
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-29
First Post:
2024-04-22
Brief Title:
The Efficacy of Repetitive Transcranial Magnetic Stimulation With Precision Neuronavigation in Parkinsons Disease
Sponsor:
Anhui Medical University
Organization:
Anhui Medical University
Study Overview
Official Title:
A Randomized Double-blind Multicenter Placebo-controlled Trial the Efficacy of Repetitive Transcranial Magnetic Stimulation With Precision Neuronavigation in Parkinsons Disease
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Repetitive transcranial magnetic stimulation rTMS is a non-invasive and widely used neuromodulation technology Small sample studies have shown that rTMS treatment can significantly improve the symptoms of Parkinsons diseasePD and delay the progression of the disease In order to further explore the effectiveness of rTMS in the treatment of PD and lay the foundation for its clinical promotion our research team plans to conduct a randomized double-blind controlled study of rTMS in the treatment of PD in multiple centers across the country
Detailed Description:
This is a multi-center double-blind randomized controlled study that will be implemented in multiple hospital centers in China In this study the supplementary motor area SMA of the dominant hemisphere was selected as the stimulation target and continuous theta burst stimulation cTBS sequence contact stimulation was used for a course of continuous stimulation for 7 days to observe the changes in clinical symptoms before and after the intervention
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None